This change frees researchers to study cannabis products that most consumers encounter when buying medical marijuana – which could accelerate its treatment potential.
Articles on Schedule I drugs
Displaying all articles
Legal recreational cannabis use comes with an increase in innovation – but tends to focus on what marketers and businesses are interested in, rather than health benefits and risks.
Psilocybin falls into a regulatory gray zone, with strict limitations around how it can be studied. As a result, very little is known about its health risks, despite its surging popularity.
The proposed rescheduling of marijuana could have far-reaching implications in science, medicine and criminal justice. What is the best policy option?
The 2018 farm bill legalized hemp products that offer a high similar to marijuana nationwide. Experts worry that lax regulations present a public health risk.
Moving marijuana to a less restrictive category under the Controlled Substances Act poses benefits and potential risks. But no effective medicine is free from risks.
The FDA’s decision shines a light on some of the unique obstacles that psychedelic drugs may face on the path to approval.
Top contributors
-
Adjunct Professor of Philosophy, George Washington University
-
Honors Faculty Fellow, Associate Teaching Professor, and Associate Director of the Center for Work & Democracy, Arizona State University
-
Fellow in Drug Policy, Rice University
-
Professor of Psychiatry, University of Colorado Anschutz
-
Associate Professor of Psychiatry, University of Colorado Anschutz
-
Professor of Resource Economics, UMass Amherst
-
Assistant Professor of Resource Economics, UMass Amherst
-
Associate Professor of Nursing, Binghamton University, State University of New York